Published in Vaccine Weekly, May 26th, 2010
Researchers from the University of Texas at Austin have developed a delivery system utilizing invasin as a targeting molecule to M cells as well as an agent that can enhance the patient's immune response. This formulation may be useful in developing countries due to its stable...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.